Literature DB >> 12626392

Epitope mapping of sialyl Lewis(x) bound to E-selectin using saturation transfer difference NMR experiments.

Meike Rinnbauer1, Beat Ernst, Bea Wagner, John Magnani, Andrew J Benie, Thomas Peters.   

Abstract

A complex between sialyl Lewisx (alpha-D-Neu5Ac-[2-->3]- beta-D-Gal-[1-->4]-[alpha-L-Fuc-(1-->3)]-beta-D-GlcNAc-O-[CH2]8 COOMe) and E-selectin was studied using saturation transfer difference (STD) nuclear magnetic resonance (NMR) experiments. These experiments allow the identification of the binding epitope of a ligand at atomic resolution. A semiquantitative analysis of STD total correlation spectroscopy spectra provides clear evidence that the galactose residue receives the largest saturation transfer. The protons H4 and H6 of the galactose residue are in especially close contact to the amino acids of the E-selectin binding pocket. The fucose residue also receives a significant saturation transfer. The GlcNAc and Neu5Ac residues, with the exception of H3 and H3' of Neu5Ac, were found to interact weakly with the protein surface. These findings are in excellent agreement with a recently published X-ray structure and with the earlier findings from syntheses and activity assays. To further characterize the binding pocket of E-selectin, an inhibitory peptide, Ac-TWDQLWDLMK-CONH2, was synthesized and the binding to E-selectin studied utilizing transfer nuclear Overhauser effect spectroscopy (trNOESY) experiments. Finally, competitive trNOESY experiments were performed, showing that the synthetic peptide is a competitive inhibitor of sialyl Lewisx.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626392     DOI: 10.1093/glycob/cwg043

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  8 in total

1.  GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Authors:  Jungshan Chang; John T Patton; Arun Sarkar; Beat Ernst; John L Magnani; Paul S Frenette
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Metabolic inhibition of sialyl-Lewis X biosynthesis by 5-thiofucose remodels the cell surface and impairs selectin-mediated cell adhesion.

Authors:  Wesley F Zandberg; Jayakanthan Kumarasamy; B Mario Pinto; David J Vocadlo
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

Review 3.  Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome.

Authors:  Madhukar S Patel; David Miranda-Nieves; Jiaxuan Chen; Carolyn A Haller; Elliot L Chaikof
Journal:  Transl Res       Date:  2016-12-09       Impact factor: 7.012

4.  Acyclic tethers mimicking subunits of polysaccharide ligands: selectin antagonists.

Authors:  Mickael Calosso; Guillaume Tambutet; Daniel Charpentier; Gabrielle St-Pierre; Marc Vaillancourt; Mohammed Bencheqroun; Jean-Philippe Gratton; Michel Prévost; Yvan Guindon
Journal:  ACS Med Chem Lett       Date:  2014-07-16       Impact factor: 4.345

5.  Shaping up for structural glycomics: a predictive protocol for oligosaccharide conformational analysis applied to N-linked glycans.

Authors:  Benedict M Sattelle; Andrew Almond
Journal:  Carbohydr Res       Date:  2013-10-30       Impact factor: 2.104

Review 6.  The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.

Authors:  Benjamin A H Smith; Carolyn R Bertozzi
Journal:  Nat Rev Drug Discov       Date:  2021-01-18       Impact factor: 84.694

Review 7.  "Rules of Engagement" of Protein-Glycoconjugate Interactions: A Molecular View Achievable by using NMR Spectroscopy and Molecular Modeling.

Authors:  Roberta Marchetti; Serge Perez; Ana Arda; Anne Imberty; Jesus Jimenez-Barbero; Alba Silipo; Antonio Molinaro
Journal:  ChemistryOpen       Date:  2016-06-07       Impact factor: 2.911

Review 8.  From carbohydrate leads to glycomimetic drugs.

Authors:  Beat Ernst; John L Magnani
Journal:  Nat Rev Drug Discov       Date:  2009-07-24       Impact factor: 84.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.